NCT03407495View on ClinicalTrials.gov

The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 22, 2018

Primary Completion Date

August 30, 2020

Study Completion Date

October 30, 2020

Conditions
Magnetic Resonance Imaging
Interventions
DRUG

IOP Injection (MPB-1523)

one dose, once IV injection at Day 1

Trial Locations (5)

100

National Taiwan University Hospital, Taipei

404

China Medical University Hospital, Taichung

407

Taichung Veterans General Hospital, Taichung

704

National Cheng Kung University Hospital, Tainan City

833

Chang Gung Medical Foundation, Kaohsiung City

All Listed Sponsors
lead

MegaPro Biomedical Co. Ltd.

INDUSTRY

NCT03407495 - The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter